Search for directed genic interactions:  

MTOR PTBP2 (1 - 1 of 1)
PMID: 23478407
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
... an mTOR inhibitor ... also acts on DCs, ...   (details)

MTOR PTBP2

Type:  regulation
Is this interaction correct?
Yes
No

Comments

Theme:  DCS   (PTBP2   HNRNPF   HNRNPH1   PTBP1 )

PMID: 23478407

Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
Source

The Journal of clinical investigation (4/1/2013)

Abstract

Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Human graft endothelial cells (ECs) can act as antigen-presenting cells to initiate allograft rejection by host memory T cells. Rapamycin, an mTOR inhibitor used clinically to suppress T cell responses, also acts on DCs, rendering them tolerogenic. Here, we report the effects of rapamycin on EC alloimmunogenicity. Compared with mock-treated cells, rapamycin-pretreated human ECs (rapa-ECs) stimulated less proliferation and cytokine secretion from allogeneic CD4+ memory cells, an effect mimicked by shRNA knockdown of mTOR or raptor in ECs. The effects of rapamycin persisted for several days and were linked to upregulation of the inhibitory molecules PD-L1 and PD-L2 on rapa-ECs. Additionally, rapa-ECs produced lower levels of the inflammatory cytokine IL-6. CD4+ memory cells activated by allogeneic rapa-ECs became hyporesponsive to restimulation in an alloantigen-specific manner and contained higher percentages of suppressive CD4+CD25hiCD127loFoxP3+ cells that did not produce effector cytokines. In a human-mouse chimeric model of allograft rejection, rapamycin pretreatment of human arterial allografts increased graft EC expression of PD-L1 and PD-L2 and reduced subsequent infiltration of allogeneic effector T cells into the artery intima and intimal expansion. Preoperative conditioning of allograft ECs with rapamycin could potentially reduce immune-mediated rejection.